Announcements

4 March 2026
MDPI’s 2025 Best Paper Awards—Award-Winning Papers Announced


MDPI is honored to announce the recipients of the 2025 Best Paper Awards, celebrating exceptional research for its scientific merit and broad impact. After a rigorous evaluation process conducted by Academic Editors, this year’s awards showcase papers that stand out for their innovation, relevance, and high-quality presentation.

Out of a highly competitive pool, 396 winning papers have been recognized for their exceptional contributions. We congratulate these authors for pushing the boundaries of their respective disciplines.

At MDPI, we are dedicated to broadening the reach of innovative science. To learn more about the award-winning papers and explore research projects in your field of study, please visit the following links:

About MDPI Awards:

To reward the global research community and enhance academic dialogue, MDPI journals regularly host award programs across diverse scientific disciplines. These awards, serving as a source of inspiration and recognition, help raise the influence of talented individuals who have been credited with outstanding achievements and whose work drives the advancement of their fields.

Explore the Best Paper Awards open for participation, please click here.

 

8 April 2026
Interview with Dr. Robert Hsu—Author of a Highly Cited Paper in Antibodies


Dr. Robet Hsu is one of the authors of the highly cited article entitled “Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions” published in Antibodies (ISSN: 2073-4468).

The following is an interview with Dr. Hsu:

1. Can you briefly introduce yourself and your current research focus?
My name is Robert Hsu. I work at  University of Southern California in Los Angeles, CA, United States. I do a lot of clinical research. My research focus is on looking at new potential biomarkers in the field of lung cancer, and I also take part in helping run clinical trials in thoracic oncology.
I also have a particular interest in trying to understand cancer disparities, not just in lung cancer, but across other solid tumor types as well.

2. How did you become interested in your current research field?
When I was training as a medical oncology fellow, I started a research project about trying to understand the molecular prevalences within our lung cancer population at our institution, given that we have quite a diverse population in terms of the patients, their backgrounds, and ethnicities. We saw some mutational differences, particularly with our Hispanic population, and this helped us to understand our population better and learn about different mutational subtypes and immunotherapy responses among those who get immunotherapy. This initial project prompted me to learn more about lung cancer.

3. Which research topics do you think will be most important in the coming years?
Certainly, there’s new classes of drugs, and the Antibodies journal is a great fit for those studies because there’s a lot of antibody drugs, whether it’s bispecific antibodies or antibody drug conjugates.
The other topic I also think is important is biomarkers and how to develop new biomarkers that could predict which patients have a response to these new classes of drugs.

4. What advice would you give to young researchers?
My first advice would be to try not to be afraid and ask around. It is also important to find a suitable mentor. Just because the first person you ask agrees to be your mentor does not necessarily mean that it is the best fit for your research goals or area of interest. It is fine to look for other research mentors if needed. Moreover, if you don’t have great experience with a researcher, that does not imply that you have to give up your pursuit in the field.
One aspect that young investigators also need to realize is that research is typically a long process; even writing a review paper takes quite a while. Many projects take years to complete, and it is important that they understand that research is not necessarily simple or quick.
Another aspect is to take into account that you can’t do it all by yourself. If you look at a paper, you will see that it is usually written by several co-authors; it is very rare to have a manuscript with just one author. To do any research, it is a collaborative process that takes a whole team to put together.

5. What prompted you to submit your work to Antibodies?

I was actually reached out to by the Antibodies Editorial Office to contribute a manuscript to a Special Issue.
It was a great experience that allowed us to explore an area I was interested in: anti-MET therapies in lung cancer. MET is a key gene seen both at de novo diagnosis and as an acquired resistance alteration in other molecular subtypes like EGFR mutant non-small cell lung cancer.
We then published a second manuscript in Antibodies earlier this year, which focused on antibody drug conjugates and bispecific T cell engagers in small cell lung cancer.
It was great to have those experiences, and I appreciate the Antibodies Editorial Office for reaching out to us.

6. We are an open access journal. How do you think open access impacts readers and authors?
I’m fortunate to be at an academic institution where I can log into my university account and access most papers. But in many of the highest impact journals, you still have to log in, and you can’t access the entire paper, which I find very frustrating. These papers should be open access, because research is meant to be shared with the greater scientific population and restricting access goes against the spirit of sharing research within the scientific community.
Therefore, I think that it’s great that Antibodies is an open access journal that provides full access to all readers.

2 April 2026
2026 Tu Youyou Award—Open for Nominations


We are delighted to announce that nominations are now open for the 2026 Tu Youyou Award. Named after Nobel Laureate Tu Youyou, whose discovery of artemisinin has saved millions of lives, this award recognizes researchers whose work advances the fields of natural products chemistry and medicinal chemistry, while also contributing to human health.

Prize

– CHF 100,000;
– A medal;
– A certificate.

The monetary prize will be shared equally should there be multiple recipients.

Who May Be Nominated?

– Scientists with outstanding achievements and contributions in the fields of natural products chemistry and medicinal chemistry.

Nominees must be individuals; team or group nominations are not permitted. Nominations are valid only for the current award cycle.

Who May Submit a Nomination?

– The director of the nominee’s host research institution or recognized scientists within the field.

Self-nominations will not be considered.

Nomination Materials

– A biographical sketch;
– A detailed description of the nominee’s contributions;
– 5–10 representative academic publications;
– A list of academic honors, awards, and funded projects;
– A nomination letter signed by two nominators.

How to Submit?

Submit nominations online via the following link: https://tuyouyouprize.org/nomination

Important Dates

– Nomination Deadline: 31 October 2026
– Winner Announcement: March 2027

For further information, please visit the Tu Youyou Award website (https://tuyouyouprize.org/). For any inquiries, please contact the Tu Youyou Award Team at tuyouyouaward@mdpi.com.

1 April 2026
Antibodies | Selected Papers on Monoclonal Antibodies


We are pleased to highlight 15 notable papers on monoclonal antibodies published in Antibodies (ISSN: 2073-4468) in 2024 and 2025. We invite you to explore these contributions, which reflect recent advances and emerging directions in monoclonal antibodies.

1. “A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments”
by Corrado Zengarini, Alba Guglielmo, Martina Mussi, Giovanna Motta, Claudio Agostinelli, Elena Sabattini, Bianca Maria Piraccini and Alessandro Pileri
Antibodies 2024, 13(2), 32; https://doi.org/10.3390/antib13020032
Available online: https://www.mdpi.com/2073-4468/13/2/32

2. “Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data”
by Connor Frey and Mahyar Etminan
Antibodies 2024, 13(3), 56; https://doi.org/10.3390/antib13030056
Available online: https://www.mdpi.com/2073-4468/13/3/56

3. “Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab”
by Silvia Zaninelli, Silvia Panna, Sarah Tettamanti, Giusi Melita, Andrea Doni, Francesca D’Autilia, Rut Valgardsdottir, Elisa Gotti, Alessandro Rambaldi, Josée Golay et al.
Antibodies 2024, 13(3), 71; https://doi.org/10.3390/antib13030071
Available online: https://www.mdpi.com/2073-4468/13/3/71

4. “Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling”
by Mokshada Kumar, Sravani Lanke, Alka Yadav, Mfonabasi Ette, Donald E. Mager and Dhaval K. Shah
Antibodies 2024, 13(3), 54; https://doi.org/10.3390/antib13030054
Available online: https://www.mdpi.com/2073-4468/13/3/54

5. “Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays”
by Wim H. M. Vroemen, Shakira S. Agata, Joyce J. B. C. van Beers and Jan G. M. C. Damoiseaux
Antibodies 2024, 13(3), 73; https://doi.org/10.3390/antib13030073
Available online: https://www.mdpi.com/2073-4468/13/3/73

6. “Cost-Effective Method for Full-Length Sequencing of Monoclonal Antibodies from Hybridoma Cells”
by Sarah Döring, Georg Tscheuschner, Sabine Flemig, Michael G. Weller and Zoltán Konthur
Antibodies 2025, 14(3), 72; https://doi.org/10.3390/antib14030072
Available online: https://www.mdpi.com/2073-4468/14/3/72

7. “Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence”
by Francois Rosset, Nadia Sciamarrelli, Luca Mastorino, Valentina Pala, Sara Boskovic, Eleonora Bongiovanni, Orsola Crespi, Yingying Liao, Simone Ribero and Pietro Quaglino
Antibodies 2025, 14(3), 79; https://doi.org/10.3390/antib14030079
Available online: https://www.mdpi.com/2073-4468/14/3/79

8. “Impact of Light-Chain Variants on the Expression of Therapeutic Monoclonal Antibodies in HEK293 and CHO Cells”
by Alexander Veber, Dennis Lenau, Polyniki Gkragkopoulou, David Kornblüh Bauer, Ingo Focken, Wulf Dirk Leuschner, Christian Beil, Sandra Weil, Ercole Rao and Thomas Langer
Antibodies 2025, 14(3), 53; https://doi.org/10.3390/antib14030053
Available online: https://www.mdpi.com/2073-4468/14/3/53

9. “Diversity in the HLA-I Recognition of HLA-F Monoclonal Antibodies: HLA-F or HLA-Ib Monospecific, HLA-E or HLA-G Bispecific Antibodies with or without HLA-Ia Reactivity”
by Mepur H. Ravindranath, Narendranath M. Ravindranath, Carly J. Amato-Menker, Fatiha El Hilali and Edward J. Filippone
Antibodies 2024, 13(1), 8; https://doi.org/10.3390/antib13010008
Available online: https://www.mdpi.com/2073-4468/13/1/8

10. “The Role of Monoclonal Antibodies as Therapeutics in HPV-Related Head and Neck Cancers: An Updated Review”
by Michael Zalin, Shaan Patel, Carter Coggins and Vikrant Rai
Antibodies 2025, 14(2), 37; https://doi.org/10.3390/antib14020037
Available online: https://www.mdpi.com/2073-4468/14/2/37

31 March 2026
MDPI INSIGHTS: The CEO’s Letter #33 - 2025 Annual Report, Preprints.org, IWD, Recapping Viruses 2026 & Romania Salon

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Scaling Open Access with Integrity: MDPI Annual Report 2025

I am pleased to share the release of MDPI’s 2025 Annual Report, reflecting our continued progress as one of the world’s leading open access publishers. The report highlights not only our growth, but also the continued evolution of our publishing model and our commitment to quality, transparency, and collaboration.

You can explore the full report here: https://mdpi-res.com/data/mdpi_annual_report_2025_0401.pdf?1775045421

Or visit the interactive page: https://www.mdpi.com/annual-report-2025/

A Year of Growth and Responsibility

2025 was a year of significant growth for MDPI. We received over 669,000 manuscript submissions, the highest in our history, while maintaining a rejection rate above 60%, reinforcing our commitment to both scale and quality.

We published 261,576 peer-reviewed open access articles across a portfolio of 500 journals, supported by a global community of more than 68,000 Editorial Board Members and 209,000 reviewers.

Scaling with Integrity

Growth alone is not the objective; how we grow matters.

Our 2025 Annual Report, Scaling Open Access with Integrity, reflects our continued focus on building the systems and processes that support reliable and trustworthy publishing. As submission volumes increase globally, so too does the importance of robust editorial workflows, research integrity frameworks, and the infrastructure required to support them.

In 2025, we continued to invest in:

  • Research integrity and quality assurance processes
  • Editorial support and reviewer engagement
  • Transparency across the publishing workflow

These efforts ensure that scale does not come at the expense of rigor, but rather reinforces it.

Validation Through Indexing and Visibility

As MDPI continues to grow, validation of quality remains essential.

In 2025, the number of MDPI journals indexed in the Web of Science Core Collection increased from 298 to 329, while Scopus coverage reached 355 journals, including 45 new acceptances. Coverage in major biomedical databases (PMC/Medline/PubMed) expanded to 95 journals, and indexing in Ei Compendex increased significantly.

These milestones reflect the strength of our editorial processes and the trust placed in our journals by independent indexing bodies.

Importantly:

  • 96% of all MDPI articles are indexed in Web of Science databases
  • More than 1.75 million articles are indexed, with an average of 13 citations per article

Recognition through Journal Citation Reports also continues to grow:

  • 298 journals received Impact Factors
  • 65% ranked in the top half of their categories
  • 61 journals achieved top-quartile positions

These developments demonstrate that growth and quality are advancing together, supported by strong editorial oversight and consistent performance across our journal portfolio.

Strengthening Partnerships and Community

Open access is a collaborative endeavor.

In 2025, we expanded our institutional partnerships to more than 1,000 IOAP agreements, helping simplify publishing for researchers and institutions worldwide.

We also hosted 60 in-person conferences and virtual events, bringing together more than 28,000 participants to exchange ideas, share research, and strengthen connections across the global scientific community.

At the heart of everything we do is this community of authors, editors, reviewers, and partners who make open science possible.

Looking Ahead

Open access continues to move toward becoming the standard model for sharing research globally. With that growth comes increased responsibility.

Our focus moving forward is to continue building a publishing ecosystem that is:

  • Collaborative, to serve the research community
  • Rigorous, to ensure quality
  • Transparent, to support trust
  • Scalable, to meet global demand

We believe that open access, when combined with strong editorial standards and integrity, is the most effective way to accelerate scientific progress.

Thank you to all the scholarly community who collaborated with us and our MDPI staff for your continued dedication and contributions in making 2025 a successful year.

Impactful Research

Celebrating Ten Years of Preprints.org: Accelerating Open Research

In 2026, MDPI’s preprints server Preprints.org marked its 10th anniversary as a platform dedicated to accelerating the dissemination of research. Since its launch, Preprints.org has grown into a global platform that hosts more than 120,000 preprints contributed by hundreds of thousands of researchers worldwide, generating tens of millions of views and downloads and demonstrating the value of sharing research openly and rapidly.

At MDPI, we are proud to celebrate ten years of Preprints.org supporting the mission of open science. Over the past decade, we have seen how early sharing of research can accelerate collaboration and help ideas move more quickly from discovery to impact.

The Evolution of Preprints

While Preprints.org launched in 2016, the idea behind it has deeper roots. The concept of rapid research dissemination has existed for decades, with early preprint servers showing how open sharing can accelerate scientific progress.

Over the past decade, preprints have become an increasingly important part of scholarly communication. Researchers across disciplines are looking at faster ways to share their discoveries, exchange ideas, and receive feedback from the global scientific community.

Preprints in a Growing Research Ecosystem

The global preprint landscape has expanded significantly over the past decade, with multiple platforms serving different research communities. The figure below (sourced from James Butcher newsletter), based on data from Dimensions (Digital Science), shows the growth of preprint outputs across several major platforms over time.

Among these platforms, arXiv (the pioneering preprint server) has experienced great growth in recent years. At the same time, other platforms have continued to expand their reach across disciplines, capturing increasing global interest in early research sharing.

Preprints.org contributes to this evolving ecosystem by providing a multidisciplinary platform that works in synergy with academic journals, helping researchers bridge the gap between rapid dissemination and the formal publication process.

Celebrating the First Decade

To commemorate this milestone, Preprints.org launched a 10th Anniversary celebration hub highlighting the impact of preprints and the researchers who contribute to them.

One of the central initiatives is the Popular Preprints of the Decade Award, recognizing influential preprints published between 2016 and 2026 across multiple research fields. Through community voting, the award will recognize research that has generated high engagement and visibility within the global research community.

Looking Ahead: The Next Decade of Preprints

As research communication continues to evolve, preprints will continue to play an important role in enabling faster collaboration, improving transparency, and expanding access to knowledge. The next decade may bring further integration between preprint platforms and journals, new tools for discovery and evaluation, and greater global participation in open science.

At MDPI, we remain committed to supporting researchers through platforms that encourage the open exchange of ideas. The success of Preprints.org over the past ten years reflects the engagement and trust of the global research community – authors, readers, reviewers, and collaborators who believe in the value of sharing knowledge openly.

Congratulations to everyone involved in the development and growth of Preprints.org over the past decade!

Inside MDPI

Beyond International Women’s Day: Supporting Women in Research

International Women’s Day (IWD) offers an opportunity to recognize the achievements of women around the world and reflect on how we can continue building a more inclusive future. In research and academia, this conversation carries particular importance, as scientific progress depends on diverse perspectives, and supporting women in science is essential to strengthening the global research ecosystem.

For MDPI, IWD is an opportunity to celebrate the achievements of women in research and highlight the initiatives, conversations, and collaborations that help support researchers across disciplines and career stages.

Highlighting Women in Science Across MDPI

This year, MDPI marked International Women’s Day with a global campaign highlighting research, awards, and perspectives that support women in science. Throughout the week, our teams shared content across MDPI’s social media channels sharing the work of women researchers and encouraging engagement across the academic community.

As part of this initiative, MDPI published several blog articles exploring important themes related to gender equity in research. One article, Give Support, Gain Progress: Retaining Women in Science, discusses the importance of mentorship, institutional support, and inclusive research environments in helping women build sustainable scientific careers.

Another featured article, Bridging the Gap in Women’s Health Research, highlights the ongoing need to address disparities in health research and ensure that women’s health receives the scientific attention and investment it deserves.

These topics capture the notion that supporting women in science benefits not only individual researchers but the entire scientific community. When researchers from diverse backgrounds can contribute their perspectives and ideas, the scope and impact of scientific discovery expand.

Creating Spaces for Dialogue

Beyond online content, MDPI is also supporting conversations about women in research through community engagement.

On 10 March, MDPI UK hosted the “Women in Research” event, bringing together researchers and professionals to share experiences and discuss the opportunities and challenges women face throughout their scientific careers. Events like these are an opportunity for open dialogue, mentorship, and networking to create more inclusive research communities.

Looking Beyond a Single Day

While IWD is an important moment of recognition, progress requires ongoing effort.

Supporting women in research involves many forms of engagement: from mentorship and collaboration to creating inclusive environments in which diverse voices are heard and valued. Publishers, institutions, and researchers all play a role in building this ecosystem.

At MDPI, we remain committed to supporting the global research community and to promoting open access publishing as a foundation for accessible and inclusive knowledge-sharing.

As we reflect on IWD this year, we recognize the many women who contribute to research as authors, reviewers, editors, mentors, and educators; we also recognize the impact they continue to have on the advancement of science. The influence of women in research extends far beyond a single day of recognition, reminding us that supporting them is a commitment that continues throughout the year.

Coming Together for Science

Highlights from Viruses 2026 – New Horizons in Virology (11–13 March)

Through 11–13 March, we successfully delivered the Viruses 2026 – New Horizons in Virology MDPI conference in Barcelona, bringing together an international community of researchers, editors, and partners dedicated to advancing the field of virology.

Conference Highlights

Viruses 2026 in numbers:

  • 198 total registrations, with 171 attendees on site
  • 233 submissions, with 122 accepted
  • 42 short talks, 9 flash talks, and 80 posters
  • 13 invited speakers and 1 keynote speaker

The strong level of participation and quality of submissions once again demonstrate the relevance of the Viruses community.

A standout moment was the keynote lecture by Dr. Ho, which also attracted an NBC documentary film crew, highlighting the broader impact of the research being presented.

Scientific Programme

The conference programme covered areas across modern virology, including viral replication, pathogenesis, immunology, and public health. Sessions explored topics on antiviral therapeutics and vaccines, innate immunity, virus–host interactions, and the structure and mechanisms of virus replication.

Together, these discussions highlighted both the fundamental biology of viruses and the translational challenges of addressing emerging infectious diseases, reflecting the breadth and continued importance of virology research in a global context. The programme also included a sponsored workshop on research data management in virology, further emphasizing the importance of data practices in advancing the field.

Thank You

Feedback from participants has been very positive, and I would like to thank the Conference team for the organization and delivery of this year’s event.

Thank you to our Viruses journal team and all colleagues involved behind the scenes in supporting the delivery of the event. As noted by Dr. Eric Freed (EiC of Viruses), the success of this edition gives us strong momentum as we look ahead to the next conference in 2028, with opportunities to further expand participation and engagement.

Closing Thoughts

Recap from MDPI Romania Salon in Cluj-Napoca (24 March)

On 24 March, we had the opportunity to meet with members of the Romanian research community in Cluj-Napoca at our MDPI Romania Salon. The event was a space for presentations, open discussion, and the exchange of perspectives on publishing and the research landscape in Romania.

We welcomed 39 participants, including 27 researchers from institutions across Romania, representing cities such as Cluj-Napoca, Timișoara, and Reșița. Among them were Editorial Board Members, Associate Editors, and Guest Editors, all of whom play an important role in collaborating with MDPI and shaping the quality and direction of academic publishing.

A Shared Commitment to Research Excellence

These events reflect MDPI’s commitment to connecting with and supporting researchers by means of transparency, dialogue, and collaboration. During the day, MDPI colleagues shared a series of presentations covering different parts of our publishing ecosystem:

  • MDPI’s presence in Romania – Anamaria Vartolomei (Journal Relationship Specialist (JRS), Section Managing Editor (ME))
  • MDPI’s performance, growth, and impact in Romania – Stefan Tochev (CEO)
  • Academic services, initiatives, and projects supporting researchers – Ioana Preda (JRS, Section ME)
  • Best practices and standards in publication ethics – Lavinia Rogojina (Research Integrity Manager)
  • Panel session on ethics, AI, and peer review – Lavinia Rogojina, Ioana Preda, Doris Larisa Albu (JRS, Section ME), Cristina Georgiana Spelmezan (JRS, Section ME)
  • Closing remarks – Lavinia Dumitrela Cozma (Operations Manager, Section ME)

Feedback from participants was very positive, particularly regarding the quality of discussions, the relevance of the topics, and the opportunity to engage directly with MDPI colleagues. What stood out most was the openness of the discussion. These events are important not only for the purposes of presenting what we do, but also as an opportunity to listen, understand concerns, and continue to build alignment with the research community.

Romania and the Growth of Open Access Publishing

The Romanian research landscape continues to show growth in open access (OA) publishing.

In 2025:

  • 72% of all publications in Romania were published as OA
  • Of these, 74% were Gold Open Access

Over the past five years, Romania has produced more than 109,000 publications, with approximately 71% available openly, highlighting a sustained shift toward accessibility and knowledge-sharing.

Within this landscape, MDPI continues to play a significant role:

  • MDPI is the leading OA publisher in Romania, contributing 42% of all OA publications in 2025
  • More than 37,000 articles have been published with MDPI by Romanian institutions since 1996
  • This figure includes over 7,500 publications in 2025 alone
  • More than 400 Editorial Board Members from Romania collaborate with MDPI across disciplines

These trends show the growth of OA and the strength of collaboration between MDPI and the Romanian research community.

Looking Ahead

As academic publishing continues to evolve, maintaining open and transparent communication with researchers is essential. Events such as our Salons and Summits provide great opportunities to exchange perspectives and to build trust and collaboration.

Thank you to all participants who joined us in Cluj, and to our teams in Romania for delivering a successful event. A special thank-you to Alina-Florina Agafitei (Marketing Specialist) for her care and attention to detail in delivering the Salon.

Stefan Tochev
Chief Executive Officer
MDPI AG

25 March 2026
Antibodies Outstanding Reviewer Award—Winner Announced


We are pleased to announce the winner of the Antibodies 2025 Outstanding Reviewer Award. The Antibodies (ISSN: 2073-4468) Editorial Board and editorial team would also like to acknowledge the time and effort dedicated by reviewers in evaluating manuscripts submitted to this journal. It is due to their contributions that Antibodies’ reputation for high quality and quick turnaround is maintained.

Winner:

  • Dr. Gloria Riitano, “Sapienza” University of Rome, Italy.

Prize:

  • CHF 500;
  • An electronic certificate;
  • A free voucher for article processing fees valid for one year.

Antibodies Editorial Office

25 March 2026
Acknowledging the Contributions of Our Reviewers in 2025


As a pioneer in open access publishing, MDPI maintains rigorous publication standards. This mission relies on the dedication and expertise of our reviewers, who invest their time and knowledge to ensure the quality and integrity of the research we publish.

In 2025, over 209,000 reviewers contributed to the peer-review process at MDPI, providing more than 1.3 million review reports for our journals. To express our gratitude, MDPI’s Reviewer Recognition Program highlights reviewers across over 400 journals, featuring those who have assessed at least one manuscript and agreed to be acknowledged.

In addition, MDPI has identified its Top 1000 Reviewers of 2024 to recognize those whose expertise, dedication, and thoughtful evaluations were particularly outstanding.

Many journals have also established Outstanding Reviewer Awards to honor our reviewers’ commitment to publication excellence. Together with the Exceptional Reviewer List, we showcase the importance of reviewers’ work and their time and dedication.

These initiatives serve to express our deepest appreciation and gratitude towards the whole reviewer community. In recognition of their contributions, we also welcome new researchers to join this community. If you would like to contribute to open access publishing, learn more about the reviewers’ benefits and sign up to join us.

20 March 2026
Meet Us at the Asia–Pacific Vaccine and Immunotherapy Congress 2026 (APVIC 2026), 6–8 May 2026, Biopolis, Singapore


Conference:
Asia–Pacific Vaccine and Immunotherapy Congress 2026 (APVIC 2026)
Date: 6–8 May 2026
Location: Matrix, Biopolis, Singapore

Join us in Singapore for the Asia–Pacific Vaccine and Immunotherapy Congress (APVIC) 2026!
This international congress brings together leading scientists, clinicians, researchers, and industry experts working at the forefront of vaccinology, immunology, and immunotherapy.

APVIC 2026 will serve as a dynamic platform for knowledge exchange and collaboration, covering cutting-edge research in vaccine development, immune responses, infectious diseases, cancer immunotherapy, translational medicine, and public health strategies. The conference aims to foster interdisciplinary dialogue and strengthen partnerships across academia, healthcare, and industry in the Asia–Pacific region and beyond.

Don’t miss this opportunity to connect with peers, share insights, and contribute to the advancement of vaccine and immunotherapy research. Register now and be part of this vibrant scientific community.

The following journals will represent MDPI at the conference:

If you are planning to attend APVIC 2026, feel free to reach out and start a conversation with us. Our team looks forward to meeting you in person and will be happy to discuss publishing opportunities or answer any questions that you may have.

For more information about the congress, please visit https://www.apvic.org/.

19 March 2026
Antibodies | Aims Update

To further enhance the quality of Antibodies (ISSN: 2073-4468) and the papers published in it, under the guidance of our Editor-in-Chief, Prof. Dr. Arne Skerra, the journal has updated and revised its aims. The original aims and the updated version are listed below: 

Aims (new version):

Aims (old version):

Antibodies (ISSN: 2073-4468) is an international, peer-reviewed open access journal that provides an advanced forum for scientific publications related to antibodies and antigens. It publishes reviews, research articles and communications. Our aim is to encourage scientists to report their experimental as well as theoretical results in as much detail as possible. There is no restriction on the maximum length of the papers. Full experimental and/or methodological details must be provided. Electronic files or software describing the full details of calculations and experimental procedures can be deposited as supplementary materials if unsuitable to be published in a normal way.

Antibodies (ISSN 2073-4468) is an international, peer-reviewed open access journal that provides an advanced forum for scientific publications related to antibodies and antigens. It publishes reviews, research articles, communications and short notes. Our aim is to encourage scientists to report their experimental as well as theoretical results in as much detail as possible. There is no restriction on the maximum length of the papers. Full experimental and/or methodological details must be provided. Electronic files or software describing the full details of calculations and experimental procedures can be deposited as supplementary materials if unsuitable to be published in a normal way.

For more detailed information, please visit the following link: https://www.mdpi.com/journal/antibodies/about.

Antibodies Editorial Office

10 March 2026
Antibodies | Selected Papers on Cancer Immunotherapy


We are pleased to highlight 15 notable papers on cancer immunotherapy published in Antibodies (ISSN: 2073-4468) in 2024 and 2025. We invite you to explore these contributions, which reflect recent advances and emerging directions in cancer immunotherapy.

1. “Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment”
by Hyukmin In, Minkyoung Park, Hyeonsik Lee and Kyung Ho Han
Antibodies 2025, 14(1), 16; https://doi.org/10.3390/antib14010016
Available online: https://www.mdpi.com/2073-4468/14/1/16

2. “TLR2 and TLR9 Blockade Using Specific Intrabodies Inhibits Inflammation-Mediated Pancreatic Cancer Cell Growth”
by Amrendra K. Ajay, Martin Gasser, Li-Li Hsiao, Thomas Böldicke and Ana Maria Waaga-Gasser
Antibodies 2024, 13(1), 11; https://doi.org/10.3390/antib13010011
Available online: https://www.mdpi.com/2073-4468/13/1/11

3. “Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions”
by Kinsley Wang and Robert Hsu
Antibodies 2024, 13(4), 88; https://doi.org/10.3390/antib13040088
Available online: https://www.mdpi.com/2073-4468/13/4/88

4. “Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers”
by Borna Rapčan, Matko Fančović, Tea Pribić, Iva Kirac, Mihaela Gaće, Frano Vučković and Gordan Lauc
Antibodies 2024, 13(1), 9; https://doi.org/10.3390/antib13010009
Available online: https://www.mdpi.com/2073-4468/13/1/9

5. “Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1”
by Julia Harwardt, Felix Klaus Geyer, Katrin Schoenfeld, David Baumstark, Vera Molkenthin and Harald Kolmar
Antibodies 2024, 13(2), 36; https://doi.org/10.3390/antib13020036
Available online: https://www.mdpi.com/2073-4468/13/2/36

6. “Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer”
by Zuhair Chaudhry, Anik Boyadzhyan, Kayvan Sasaninia and Vikrant Rai
Antibodies 2024, 13(2), 46; https://doi.org/10.3390/antib13020046
Available online: https://www.mdpi.com/2073-4468/13/2/46

7. “Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer”
by Isis Wolf, Susanne Schultze-Seemann, Christian Gratzke and Philipp Wolf
Antibodies 2025, 14(1), 5; https://doi.org/10.3390/antib14010005
Available online: https://www.mdpi.com/2073-4468/14/1/5

8. “Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy”
by Seungmin Shin, Du-San Baek, John W. Mellors, Dimiter S. Dimitrov and Wei Li
Antibodies 2025, 14(1), 21; https://doi.org/10.3390/antib14010021
Available online: https://www.mdpi.com/2073-4468/14/1/21

9. “Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy”
by Chuan Chen, Zehua Sun, Zening Wang, Seungmin Shin, Abigail Berrios, John W. Mellors, Dimiter S. Dimitrov and Wei Li
Antibodies 2024, 13(2), 39; https://doi.org/10.3390/antib13020039
Available online: https://www.mdpi.com/2073-4468/13/2/39

10. “177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model”
by Bok-Nam Park, Young-Sil An, Su-Min Kim, Su-Jin Lee, Yong-Jin Park and Joon-Kee Yoon
Antibodies 2024, 13(3), 51; https://doi.org/10.3390/antib13030051
Available online: https://www.mdpi.com/2073-4468/13/3/51

11. “Preventative Cancer Vaccine-Elicited Human Anti-MUC1 Antibodies Have Multiple Effector Functions”
by Michelle L. McKeague, Jason Lohmueller, Matthew T. Dracz, Najla Saadallah, Eric D. Ricci, Donella M. Beckwith, Ramya Ayyalasomayajula, Maré Cudic and Olivera J. Finn
Antibodies 2024, 13(4), 85; https://doi.org/10.3390/antib13040085
Available online: https://www.mdpi.com/2073-4468/13/4/85

12. “Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies”
by Ge Yang and Mohammad Massumi
Antibodies 2025, 14(3), 52; https://doi.org/10.3390/antib14030052
Available online: https://www.mdpi.com/2073-4468/14/3/52

13. “A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide”
by Ge Yang, Shahryar Khoshtinat Nikkhoi, Hajar Owji, Geng Li, Mohammad Massumi, Jessica Cervelli, Venu Gopal Vandavasi and Arash Hatefi
Antibodies 2024, 13(3), 75; https://doi.org/10.3390/antib13030075
Available online: https://www.mdpi.com/2073-4468/13/3/75

14. “Comparative Evaluation of Three Primary Antibody Clones for p16 Immunohistochemistry in Gynecologic Tumors”
by Hiroshi Yoshida, Ayumi Sugitani, Mayumi Kobayashi-Kato, Masaya Uno and Mitsuya Ishikawa
Antibodies 2025, 14(3), 77; https://doi.org/10.3390/antib14030077
Available online: https://www.mdpi.com/2073-4468/14/3/77

15. “Generation Using Phage-Display of pH-Dependent Antibodies Against the Tumor-Associated Antigen AXL”
by Tristan Mangeat, Célestine Mairaville, Myriam Chentouf, Madeline Neiveyans, Martine Pugnière, Giang Ngo, Vincent Denis, Corentin Catherine, Alexandre Pichard, Emmanuel Deshayes et al.
Antibodies 2025, 14(4), 83; https://doi.org/10.3390/antib14040083
Available online: https://www.mdpi.com/2073-4468/14/4/83

Back to TopTop